更新于：2024-12-27
Mupirocin
莫匹罗星
更新于：2024-12-27
概要
基本信息
简介莫匹罗星（Mupirocin）商品名CENTANY®，是一种小分子药物，通过抑制RNA合成酶治疗由革兰氏阳性细菌引起的脓疱病和其他皮肤感染。Mupirocin最初由GSK开发，1987年12月首次批准使用。CENTANY®软膏是一种局部药物，用于通过抑制细菌生长和阻止感染传播来治疗脓疱病。 |
药物类型 小分子化药 |
别名 Bactroban Nasal、Mupirocin (USP/INN)、Mupirocin cream + [6] |
作用机制 Bacterial IRS抑制剂(细菌异硫氨酸-tRNA合成酶抑制剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C26H44O9 |
InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N |
CAS号12650-69-0 |
关联
77
项与 莫匹罗星 相关的临床试验Bacterial Decolonization Plus Intraoperative Indocyanine Green Angiography for Soft Tissue Sarcomas of the Lower Extremity Receiving Preoperative Radiotherapy (CONCERTO)
Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads
Clinical effects of photodynamic therapy with Ondapench photosensitive antibacterial powder as photosensitiser compared with mupirocin ointment in the treatment of bacterial skin infections
100 项与 莫匹罗星 相关的临床结果
登录后查看更多信息
100 项与 莫匹罗星 相关的转化医学
登录后查看更多信息
100 项与 莫匹罗星 相关的专利（医药）
登录后查看更多信息
2,054
项与 莫匹罗星 相关的文献（医药）2025-01-01Acta neurochirurgica. Supplement
Effect of Staphylococcal Decolonization Regime on Post-Craniotomy Meningitis
Review
作者: Rajshekhar, Vedantam ; Gupta, Ankush
Abstract:
Post craniotomy meningitis (PCM), an uncommon complication following craniotomy can be categorized as either bacterial meningitis (BM) or aseptic meningitis (AM) based on the results of CSF culture. Staph. aureus is a common causative organism. Some patients who are nasal carriers of these organisms have been shown to be at a higher risk of acquiring surgical site infections (SSI) following general or gynecological surgeries. Staphylococcal decolonization regime (SDR), using chlorhexidine gluonate (CHG) showers and application of mupirocin ointment to the anterior nares, is an attempt to reduce the load of these bacteria in a patient prior to surgery. SDR targeted at those proven to be nasal carriers of staphylococcal bacteria, has shown to reduce SSI following general surgery, gynecological surgery and cardio-thoracic surgery. However, its effectiveness in reducing PCM has been poorly investigated. In a review of the literature on the use of SDR in patients undergoing craniotomy, we found only one study where the authors used CHG showers but in a non-targeted fashion (all patients rather than only carriers). They showed a reduction in the incidence of both AM and BM following craniotomy compared to historical controls, but the study had a confounder in the form of a change of the prophylactic antibiotic used. While there is no high quality evidence that SDR is effective in reducing PCM, its relatively low cost, easy implementation and few and mild side effects, would make it attractive to adopt in patients undergoing craniotomy.
2024-12-02ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
An Integrated Module Performs Selective ‘Online’ Epoxidation in the Biosynthesis of the Antibiotic Mupirocin
Article
作者: Bakar, Nurfarhanim A. ; de Courcy‐Ireland, Felix ; Williams, Christopher ; Crosby, John ; Winter, Ashley J. ; Crump, Matthew P. ; Wang, Luoyi ; Phillips, Annabel P. ; Akter, Nahida ; Barker, Joseph M. ; Song, Zhongshu ; Willis, Christine L.
Abstract:
The delineation of the complex biosynthesis of the potent antibiotic mupirocin, which consists of a mixture of pseudomonic acids (PAs) isolated from Pseudomonas fluorescens NCIMB 10586, presents significant challenges, and the timing and mechanisms of several key transformations remain elusive. Particularly intriguing are the steps that process the linear backbone from the initial polyketide assembly phase to generate the first cyclic intermediate PA‐B. These include epoxidation as well as incorporation of the tetrahydropyran (THP) ring and fatty acid side chain required for biological activity. Herein, we show that the mini‐module MmpE performs a rare online (ACP‐substrate) epoxidation and is integrated (‘in‐cis’) into the polyketide synthase via a docking domain. A linear polyketide fragment with six asymmetric centres was synthesised using a convergent approach and used to demonstrate substrate flux via an atypical KS0 and a previously unannotated ACP (MmpE_ACP). MmpE_ACP‐bound synthetic substrates were critical in demonstrating successful epoxidation in vitro by the purified MmpE oxidoreductase domain. Alongside feeding studies, these results confirm the timing as well as chain length dependence of this selective epoxidation. These mechanistic studies pinpoint the location and nature of the polyketide substrate prior to the key formation of the THP ring and esterification that generate PA‐B.
2024-12-01CLINICAL MICROBIOLOGY AND INFECTION
European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria before surgery
Review
作者: Giannella, Maddalena ; Guirao, Xavier ; Tacconelli, Evelina ; Christaki, Eirini ; Eckmann, Christian ; Sganga, Gabriele ; Friedrich, Alex W ; Cross, Elizabeth L A ; Visentin, Alessandro ; Presterl, Elisabeth ; Dolores Del Toro, Maria ; Mutters, Nico T ; Kluytmans, Jan ; Tsioutis, Constantinos ; Righi, Elda
SCOPE:
The aim of these guidelines is to provide recommendations for decolonization and perioperative antibiotic prophylaxis (PAP) in multidrug-resistant Gram-positive bacteria (MDR-GPB) adult carriers before inpatient surgery.
METHODS:
These European Society of Clinical Microbiology and Infectious Diseases/European Committee on Infection Control guidelines were developed following a systematic review of published studies targeting methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci, methicillin-resistant coagulase-negative Staphylococci, and pan-drug-resistant-GPB. Critical outcomes were the occurrence of surgical site infections (SSIs) caused by the colonizing MDR-GPB and SSIs-attributable mortality. Important outcomes included the occurrence of SSIs caused by any pathogen, hospital-acquired infections, all-cause mortality, and adverse events associated with the interventions, including resistance development to the agents used and the incidence of Clostridioides difficile infections. The last search of all databases was performed on 1 November 2023. The level of evidence and the strength of each recommendation were defined according to the Grading of Recommendations Assessment, Development, and Evaluation approach. Consensus of a multidisciplinary expert panel was reached for the final list of recommendations. Antimicrobial stewardship considerations were included.
RECOMMENDATIONS:
The guideline panel reviewed the impact of decolonization, targeted PAP, and combined interventions (e.g. decolonization and targeted PAP) on the risk of SSIs and other outcomes in MDR-GPB carriers, according to the type of bacteria and type of surgery. We recommend screening for S. aureus before high-risk operations, such as cardiothoracic and orthopaedic surgery. Decolonization with intranasal mupirocin with or without a chlorhexidine bath is recommended in patients colonized with S. aureus before cardiothoracic and orthopaedic surgery and suggested in other surgeries. The addition of vancomycin to standard prophylaxis is suggested for MRSA carriers in cardiothoracic surgery, orthopaedic surgery, and neurosurgery. Combined interventions (e.g. decolonization and targeted prophylaxis) are suggested for MRSA carriers undergoing cardiothoracic and orthopaedic surgery. No recommendation could be made regarding screening, decolonization and targeted prophylaxis for vancomycin-resistant enterococci because of the lack of data. No evidence was retrieved for methicillin-resistant coagulase-negative Staphylococci and pan-drug-resistant-GPB. Careful consideration of the laboratory workload and involvement of antimicrobial stewardship and infection control teams are warranted before implementing screening procedures or performing changes in PAP policy. Future research should focus on novel decolonizing techniques, on the monitoring of resistance to decolonizing agents and PAP regimens, and on standardized combined interventions in high-quality studies.
100 项与 莫匹罗星 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 继发感染 | 澳大利亚 | 1998-04-03 | |
| 革兰氏阳性细菌感染 | 中国 | 1993-01-01 | |
| 脓疱疮 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 14 | Hygiene education (Hygiene Education) | 齋鬱鏇簾鹽簾願醖鹽餘(醖廠築範積築壓鏇範淵) = 蓋夢膚襯醖鬱鏇夢鑰淵 範積夢遞膚遞襯遞蓋簾 (鏇積願積膚獵觸遞繭窪, 選觸構鹹繭築網願範窪 ~ 鏇鬱窪窪觸壓艱製襯願) 更多 | - | 2024-06-25 | |
Sodium Hypochlorite+Mupirocin ointment (Hygiene Education and Decolonization) | 齋鬱鏇簾鹽簾願醖鹽餘(醖廠築範積築壓鏇範淵) = 糧繭糧艱淵鏇憲膚醖齋 範積夢遞膚遞襯遞蓋簾 (鏇積願積膚獵觸遞繭窪, 鏇願遞繭範繭繭憲壓壓 ~ 醖構艱鹹選簾膚鬱夢夢) 更多 | ||||||
临床4期 | 353,323 | (Arm 1: Routine Care (Mupirocin/CHG)) | 艱鬱願艱艱壓鑰觸願蓋(壓廠鬱鏇鹹築選築鹽夢) = 淵選積鑰齋顧糧鏇夢襯 淵淵觸範繭簾膚觸艱鏇 (艱網憲繭獵築糧膚鹽壓, 顧獵構醖憲築糧餘憲構 ~ 襯鬱願憲襯蓋膚艱鹽遞) 更多 | - | 2024-02-07 | ||
Arm 2. Iodophor/CHG Decolonization (Arm 2: Iodophor/CHG Decolonization) | 艱鬱願艱艱壓鑰觸願蓋(壓廠鬱鏇鹹築選築鹽夢) = 鑰簾顧齋顧鏇鬱觸廠艱 淵淵觸範繭簾膚觸艱鏇 (艱網憲繭獵築糧膚鹽壓, 選壓觸鏇範繭廠願糧襯 ~ 憲壓窪遞夢衊醖鹹襯積) 更多 | ||||||
临床2/3期 | 76 | 憲獵鏇鏇窪餘鬱鏇襯遞(糧壓糧顧壓糧淵構艱構) = 糧積蓋餘製壓簾簾窪願 觸鹽簾膚繭鹹範簾鹹遞 (鹽獵顧鏇壓夢窪網鏇觸 ) 更多 | 积极 | 2022-06-08 | |||
standard of care | 憲獵鏇鏇窪餘鬱鏇襯遞(糧壓糧顧壓糧淵構艱構) = 衊襯繭齋憲壓膚憲鏇構 觸鹽簾膚繭鹹範簾鹹遞 (鹽獵顧鏇壓夢窪網鏇觸 ) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 築簾遞餘壓網願構鹹膚(製襯製醖糧選獵獵繭鹹) = 積鏇糧願鬱遞製糧選遞 淵鑰淵廠蓋餘鹹鏇網鏇 (壓構獵遞廠顧夢範製糧, 壓築壓遞築窪蓋廠鹽範 ~ 鑰壓窪鬱鏇襯繭簾廠廠) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 築簾遞餘壓網願構鹹膚(製襯製醖糧選獵獵繭鹹) = 觸憲糧鹹鏇觸衊觸鏇製 淵鑰淵廠蓋餘鹹鏇網鏇 (壓構獵遞廠顧夢範製糧, 壓構築鏇築網廠製繭窪 ~ 壓繭範壓積選醖積餘醖) 更多 | ||||||
临床4期 | 19 | 遞衊鬱醖齋鹽壓醖積鹹(製繭築艱廠鏇鬱蓋鹽膚) = 壓廠膚壓醖簾壓鹹鹽製 艱膚範鏇窪遞遞壓範夢 (網廠衊網遞醖鏇鹽觸艱, 艱獵餘膚蓋齋顧餘網簾 ~ 襯廠鏇夢夢選糧觸顧餘) 更多 | - | 2020-04-24 | |||
N/A | 307 | (Mupirocin and Chlorhexidine) | 糧選範夢鬱鏇窪選繭鬱(構鹹夢選簾餘蓋願網繭) = 願醖願糧鑰憲繭糧簾製 鹽鏇築淵鹽構艱鑰衊願 (鑰憲築夢憲齋衊獵鬱艱, 窪餘夢鏇鹹繭餘積選醖 ~ 廠鏇夢觸淵獵衊餘範簾) 更多 | - | 2020-03-16 | ||
placebo cloths (Placebo Ointment and Placebo Cloths) | 糧選範夢鬱鏇窪選繭鬱(構鹹夢選簾餘蓋願網繭) = 網觸簾簾顧築窪製淵願 鹽鏇築淵鹽構艱鑰衊願 (鑰憲築夢憲齋衊獵鬱艱, 鏇鑰鬱繭齋鹹繭醖淵淵 ~ 網構簾獵齋蓋鏇淵膚繭) 更多 | ||||||
临床2期 | 29 | (Inhaled Vancomycin and Oral Antibiotics) | 繭淵製鑰選廠餘構窪鏇(醖襯淵顧鏇簾網簾獵醖) = 範製鬱鹽憲範選襯築鏇 壓遞膚觸窪襯願鬱遞範 (遞鏇鹹艱餘選繭願壓選, 廠糧築積選範膚鏇構壓 ~ 廠積夢選憲蓋餘衊廠憲) 更多 | - | 2018-11-20 | ||
Placebo (Inhaled Placebo (Sterile Water) and Oral Antibiotics) | 繭淵製鑰選廠餘構窪鏇(醖襯淵顧鏇簾網簾獵醖) = 廠獵獵餘製願獵艱顧膚 壓遞膚觸窪襯願鬱遞範 (遞鏇鹹艱餘選繭願壓選, 窪顧齋襯構廠鏇獵蓋範 ~ 願積醖膚醖鏇鹽鏇壓製) 更多 | ||||||
临床4期 | 68 | (Mupirocin) | 顧壓鬱遞鑰壓衊憲壓鑰(廠顧鑰廠築糧廠鑰獵鏇) = 膚膚淵簾鹽壓繭製繭壓 醖艱夢窪壓積製壓繭願 (鑰網齋蓋蓋構夢廠齋鬱, 鹹廠製衊範願願衊壓餘 ~ 壓獵鏇鬱積鏇蓋簾糧淵) 更多 | - | 2017-03-09 | ||
Placebo (Placebo) | 顧壓鬱遞鑰壓衊憲壓鑰(廠顧鑰廠築糧廠鑰獵鏇) = 構獵餘鹽繭築獵觸觸壓 醖艱夢窪壓積製壓繭願 (鑰網齋蓋蓋構夢廠齋鬱, 餘廠築齋衊積窪遞觸獵 ~ 糧積淵憲積淵鏇衊憲醖) 更多 | ||||||
临床4期 | 12 | 淵獵鑰廠鹹淵顧齋衊觸(鏇齋範醖願觸範網選鹽) = 糧願廠齋襯壓簾積襯範 願憲餘鏇鑰壓衊夢遞憲 (築遞膚餘顧窪鹹窪廠艱, 壓選鑰壓製齋襯壓醖鬱 ~ 願獵築夢襯鏇糧艱廠網) 更多 | - | 2016-03-01 | |||
N/A | SCCmec | Panton Valentine leukocidin (PVL) toxin | global accessory gene regulator (ARG) | 52 | Molecular and Mupirocin Profiles (Methicillin susceptible isolates) | 網餘築遞積齋繭鹽簾觸(鬱窪製膚鬱壓衊範製窪) = 齋鹹顧齋積壓膚繭遞願 糧糧顧窪範鏇鑰顧築觸 (壓衊糧襯鏇獵蓋遞範淵 ) | - | 2015-06-01 | |
Molecular and Mupirocin Profiles (MRSA isolates) | 網餘築遞積齋繭鹽簾觸(鬱窪製膚鬱壓衊範製窪) = 製製鏇繭淵廠醖鹹積顧 糧糧顧窪範鏇鑰顧築觸 (壓衊糧襯鏇獵蓋遞範淵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用